Maxim Group Reiterates Buy on Viking Therapeutics, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Naz Rahman has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $120 price target.
June 04, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group analyst Naz Rahman has reiterated a Buy rating on Viking Therapeutics and maintained a $120 price target.
The reiteration of a Buy rating and a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100